Skip to main content
Premium Trial:

Request an Annual Quote

HTG Licenses Merck's Breast Cancer Biomarker Patent Portfolio

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced it has licensed Merck's breast cancer biomarker patent portfolio.

The license allows HTG to develop, manufacture, and commercialize tests based on the portfolio, which is co-owned by the Netherlands Cancer Institute. Financial and other terms of the deal were not disclosed.

HTG CEO T.J. Johnson said that the firm intends to pursue approval from the US Food and Drug Administration for tests that provide "compelling medical value" and to make them available to local laboratories. "This patent portfolio license from Merck gives HTG access to key intellectual property to bring valuable breast cancer tests to market," he said in a statement.

Based in Tucson, Ariz., HTG announced in June a partnership with the John Wayne Cancer Institute to commercialize melanoma assays. Earlier in the year it inked a companion diagnostic deal with Sanofi US.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more